Read more

September 06, 2019
2 min read
Save

5 recent highlights in IBS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recently published studies have demonstrated new developments in diarrhea- and constipation-predominant irritable bowel syndrome, as well as peppermint oil as a treatment for the condition.

In case you missed it, the editors of Healio Gastroenterology and Liver Disease have compiled a recap of some of our most recent popular articles involving IBS.

Peppermint oil ‘should not be ignored’ for IBS

Although it did not meet stringent recommended endpoints dictated by the FDA and European Medicines Agency, small intestinal-release peppermint oil reduced abdominal pain, discomfort and severity in patients with irritable bowel syndrome, according to study results.

Zsa Zsa Weerts, PhD, of the division of the gastroenterology and hepatology at Maastricht University Medical Centre, the Netherlands, and colleagues wrote that despite medical advances, patients often find therapeutic options for IBS unsatisfactory. READ MORE.

Patients with IBS-D, IBS-C find their lives impacted in different ways

Although patients with diarrhea- and constipation-predominant irritable bowel syndrome tend to find their condition equally bothersome, they find their lives impacted in different ways, according to survey results.

Sarah Ballou, PhD, of the division of gastroenterology at Beth Israel Deaconess Medical Center, and colleagues wrote that the impact of IBS on patients’ work lives is well documented, but only a few small studies have looked at its impact on social interaction and daily living. READ MORE.

Fecal transplant no better than placebo for IBS-D

Researchers cut a trial short after fecal microbiota transplantation failed to provide symptom relief better than that of placebo in patients with diarrhea-predominant irritable bowel syndrome.

Olga C. Aroniadis, MD, of the department of internal medicine at Montefiore Medical Center, and colleagues wrote in The Lancet Gastroenterology & Hepatology that previous studies have reported conflicting results for the efficacy of FMT for IBS. Two randomized controlled trials reported that patients experience significant improvement, while two others found no such benefit. READ MORE.

GI, psychological symptoms overlap in IBS-D, functional diarrhea

Researchers from Beth Israel Deaconess Medical Center identified an overlap of gastrointestinal and psychosomatic symptoms between patients with diarrhea-predominant irritable bowel syndrome and functional diarrhea.

Anthony Lembo, MD, director of motility services at BIDMC, and colleagues wrote that a diagnosis of functional diarrhea requires an exclusion of IBS-D, but the Rome IV consensus statement acknowledges functional disorders, like IBS and other non-IBS diagnoses, exist on a continuum. READ MORE.

IBgard releases data to show safety, tolerability of peppermint oil for IBS

In a postmarketing study, the manufacturer of IBgard showed that over-the-counter peppermint oil treatment effectively managed symptoms of irritable bowel syndrome without the side effect of heartburn.

In the Irritable Bowel Syndrome Safety Update at 36 Months (IBSSU36), researchers used a real-world surveillance study and reported on the safety and tolerability profile of IBgard (IM HealthScience). READ MORE.